NOVARTIS PHARMACEUTICALS

Identifying MET ex14 in mNSCLC may unlock the option for first-line targeted therapy with TABRECTA 2... MET ex14 has a prevalence of 3%, representing 4,000-5,000 patients with mNSCLC per year in the United States 18,19†... Find out why, when, and how to test for biomarkers in mNSCLC, including MET ex14, and learn about the FDA-approved companion diagnostics for TABRECTA® (capmatinib) tablets.

Also known as: MET ex14, Novartis Pharmaceuticals Corporation